[go: up one dir, main page]

EA201200618A1 - Производные хроменона с антиопухолевой активностью - Google Patents

Производные хроменона с антиопухолевой активностью

Info

Publication number
EA201200618A1
EA201200618A1 EA201200618A EA201200618A EA201200618A1 EA 201200618 A1 EA201200618 A1 EA 201200618A1 EA 201200618 A EA201200618 A EA 201200618A EA 201200618 A EA201200618 A EA 201200618A EA 201200618 A1 EA201200618 A1 EA 201200618A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
chromenon
tumor activity
medicament
manufacture
Prior art date
Application number
EA201200618A
Other languages
English (en)
Other versions
EA020523B1 (ru
EA020523B9 (ru
Inventor
Бернар Кристоф Барлам
Себастьен Луи Дегорс
Кристин Мари Поль Ламбер-Ван Дер-Бремт
Реми Робер Моржентен
Патрик Пле
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201200618A1 publication Critical patent/EA201200618A1/ru
Publication of EA020523B1 publication Critical patent/EA020523B1/ru
Publication of EA020523B9 publication Critical patent/EA020523B9/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение касается производных хроменона формулы Iили их фармацевтически приемлемых солей, где каждый из R, R, R, R, R, R, R, R, n и Rимеет любое из значений, определенных выше в описании; способов их получения, фармацевтических композиций, их содержащих, и их применения при изготовлении лекарственного средства для применения для лечения клеточных пролиферативных нарушений.
EA201200618A 2009-10-27 2010-10-25 Производные хроменона с антиопухолевой активностью EA020523B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27
PCT/GB2010/051788 WO2011051704A1 (en) 2009-10-27 2010-10-25 Chromenone derivatives with anti-tumour activity

Publications (3)

Publication Number Publication Date
EA201200618A1 true EA201200618A1 (ru) 2012-12-28
EA020523B1 EA020523B1 (ru) 2014-11-28
EA020523B9 EA020523B9 (ru) 2015-01-30

Family

ID=43085922

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200618A EA020523B9 (ru) 2009-10-27 2010-10-25 Производные хроменона с антиопухолевой активностью

Country Status (41)

Country Link
US (5) US8399460B2 (ru)
EP (1) EP2493870B1 (ru)
JP (2) JP5657010B2 (ru)
KR (1) KR101738195B1 (ru)
CN (2) CN102712615B (ru)
AR (1) AR078786A1 (ru)
AU (1) AU2010311107B9 (ru)
BR (1) BR112012010124B8 (ru)
CA (1) CA2776994C (ru)
CL (1) CL2012001056A1 (ru)
CO (1) CO6541528A2 (ru)
CR (1) CR20120217A (ru)
CU (1) CU20120069A7 (ru)
CY (1) CY1116143T1 (ru)
DK (1) DK2493870T3 (ru)
DO (1) DOP2012000124A (ru)
EA (1) EA020523B9 (ru)
EC (1) ECSP12011838A (ru)
ES (1) ES2530943T3 (ru)
GT (1) GT201200126A (ru)
HN (1) HN2012000889A (ru)
HR (1) HRP20150146T1 (ru)
IL (1) IL219191A0 (ru)
IN (1) IN2012DN03328A (ru)
ME (1) ME02050B (ru)
MX (1) MX2012005027A (ru)
MY (1) MY179833A (ru)
NI (1) NI201200081A (ru)
NZ (1) NZ599457A (ru)
PE (1) PE20130149A1 (ru)
PH (1) PH12012500804A1 (ru)
PL (1) PL2493870T3 (ru)
PT (1) PT2493870E (ru)
RS (1) RS53813B1 (ru)
SA (1) SA110310808B1 (ru)
SI (1) SI2493870T1 (ru)
SM (1) SMT201500036B (ru)
TW (1) TWI483939B (ru)
UA (1) UA107474C2 (ru)
UY (1) UY32978A (ru)
WO (1) WO2011051704A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
US9156831B2 (en) 2013-01-23 2015-10-13 Astrazeneca Ab Chemical compounds
ES2754034T3 (es) * 2013-03-04 2020-04-15 Astrazeneca Ab Combinación para el tratamiento de cáncer
AU2015274628B2 (en) 2014-06-13 2018-03-15 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
JP6383810B2 (ja) 2014-06-13 2018-08-29 ギリアード サイエンシーズ, インコーポレイテッド ホスファチジルイノシトール3−キナーゼ阻害剤としてのキナゾリノン誘導体
NZ726608A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
EA201692265A1 (ru) 2014-06-13 2017-05-31 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ, インコーポレイテッド ホスファチジルイノシトール3−キナーゼ阻害剤
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN108349946B (zh) * 2015-10-09 2021-05-18 詹森药业有限公司 作为PI3Kβ抑制剂的喹喔啉和吡啶并吡嗪衍生物
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
US20240166617A1 (en) * 2021-02-01 2024-05-23 Geode Therapeutics Inc. Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
AU2022268900B2 (en) * 2021-05-03 2024-12-19 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
KR20240004744A (ko) * 2021-05-03 2024-01-11 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
BR112023022890A2 (pt) 2021-05-27 2024-01-23 Petra Pharma Corp Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20250136568A1 (en) * 2021-12-08 2025-05-01 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer
TW202506119A (zh) * 2023-08-02 2025-02-16 大陸商鄭州同源康醫藥有限公司 稠環類化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
JPH04502322A (ja) 1988-12-21 1992-04-23 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性1―ベンゾピラン―4―オン類および2―アミノ―1,3―ベンゾオキサジン―4―オン類
DK0525123T3 (da) 1990-06-20 1998-05-04 Upjohn Co Antiatherosklerotiske og antithrombotiske 1-benzopyran-4-oner og 2-amino-1,3-benzoxazin-4-oner
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ530832A (en) 1999-02-10 2005-05-27 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
AU2001230426C1 (en) 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
UA73993C2 (ru) 2000-06-06 2005-10-17 Астразенека Аб Хиназолиновые производные для лечения опухолей и фармацевтическая композиция
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
CA2495661C (en) * 2002-08-16 2011-06-14 Kinacia Pty Ltd. Inhibition of phosphoinositide 3-kinase beta
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
CA2620248A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
CN101448505A (zh) * 2006-04-04 2009-06-03 加利福尼亚大学董事会 Pi3激酶拮抗剂
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
EA020523B1 (ru) 2014-11-28
US20110098271A1 (en) 2011-04-28
ES2530943T3 (es) 2015-03-09
MY179833A (en) 2020-11-17
HK1206335A1 (zh) 2016-01-08
JP5872016B2 (ja) 2016-03-01
RS53813B1 (en) 2015-06-30
SMT201500036B (it) 2015-05-05
HRP20150146T1 (hr) 2015-05-22
CA2776994A1 (en) 2011-05-05
DOP2012000124A (es) 2012-07-15
JP2015078202A (ja) 2015-04-23
PL2493870T3 (pl) 2015-04-30
NZ599457A (en) 2014-04-30
DK2493870T3 (en) 2015-02-23
EP2493870B1 (en) 2014-12-17
US20130158026A1 (en) 2013-06-20
UA107474C2 (ru) 2015-01-12
KR101738195B1 (ko) 2017-05-19
BR112012010124B8 (pt) 2021-05-25
US20160060240A1 (en) 2016-03-03
EA020523B9 (ru) 2015-01-30
CR20120217A (es) 2012-06-28
US8399460B2 (en) 2013-03-19
WO2011051704A1 (en) 2011-05-05
CN102712615B (zh) 2014-12-17
BR112012010124A2 (pt) 2016-06-07
UY32978A (es) 2011-05-31
PE20130149A1 (es) 2013-03-10
TWI483939B (zh) 2015-05-11
AU2010311107A1 (en) 2012-05-03
US9029374B2 (en) 2015-05-12
JP2013508449A (ja) 2013-03-07
CA2776994C (en) 2017-10-31
PT2493870E (pt) 2015-02-18
NI201200081A (es) 2012-11-07
CO6541528A2 (es) 2012-10-16
GT201200126A (es) 2014-03-03
SI2493870T1 (sl) 2015-03-31
US8673906B2 (en) 2014-03-18
TW201121960A (en) 2011-07-01
AU2010311107B2 (en) 2014-03-27
CY1116143T1 (el) 2017-02-08
CU20120069A7 (es) 2012-10-15
AR078786A1 (es) 2011-11-30
MX2012005027A (es) 2012-09-07
HN2012000889A (es) 2015-08-03
CN104447657A (zh) 2015-03-25
KR20120098724A (ko) 2012-09-05
ME02050B (me) 2015-05-20
EP2493870A1 (en) 2012-09-05
CN102712615A (zh) 2012-10-03
CN104447657B (zh) 2016-08-17
US20160272607A1 (en) 2016-09-22
IL219191A0 (en) 2012-06-28
BR112012010124B1 (pt) 2021-02-17
ECSP12011838A (es) 2012-06-29
HK1174027A1 (en) 2013-05-31
JP5657010B2 (ja) 2015-01-21
AU2010311107B9 (en) 2014-06-19
PH12012500804A1 (en) 2022-10-03
US9718800B2 (en) 2017-08-01
SA110310808B1 (ar) 2013-11-24
IN2012DN03328A (ru) 2015-10-23
CL2012001056A1 (es) 2012-10-05
US20140194419A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
EA201200618A1 (ru) Производные хроменона с антиопухолевой активностью
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
IN2014DN09434A (ru)
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
MX2013012588A (es) Inhibidores de cinasa.
IN2015DN01119A (ru)
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
BR112013026397A2 (pt) Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer
MX2012000166A (es) Compuestos de quinazolina que contienen fosforo y metodos de uso de los mismos.
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
EA201290694A1 (ru) Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ